Free Cash Flow (FCF): $412.20M
The free cash flow (FCF) is $412.20M. It is above its 12-month average by 11.14% ($370.90M).
PODD Free Cash Flow (FCF)
Reported quarterly free cash flow; no daily interpolation.
PODD Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
PODD Average Free Cash Flow (FCF) Chart
PODD Current vs Average Free Cash Flow (FCF) Chart
PODD Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$412.20M
FREE CASH FLOW (FCF) AVG TTM
$370.90M
FREE CASH FLOW (FCF) AVG 3Y
$209.97M
FREE CASH FLOW (FCF) AVG 5Y
$85.08M
FREE CASH FLOW (FCF) AVG 10Y
$-63.65M
FREE CASH FLOW (FCF) AVG 15Y
$-38.74M
FREE CASH FLOW (FCF) AVG 20Y
$-47.51M
CURRENT VS TTM AVG
+11.14%
CURRENT VS 3Y AVG
+96.31%
CURRENT VS 5Y AVG
+384.47%
CURRENT VS 10Y AVG
+747.56%
CURRENT VS 15Y AVG
+1164.12%
CURRENT VS 20Y AVG
+967.61%
FCF Analysis
Free Cash Flow (TTM)
$412.20M
FCF Yield
3.94%
Price/FCF
25.4
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Insulet Corp. (PODD)?
- The free cash flow (FCF) for PODD stock is $412.20M.
- What is the TTM average free cash flow (FCF) for Insulet Corp. (PODD)?
- The TTM average free cash flow (FCF) for PODD stock is $370.90M.
- What is the 3Y average free cash flow (FCF) for Insulet Corp. (PODD)?
- The 3Y average free cash flow (FCF) for PODD stock is $209.97M.
- What is the 5Y average free cash flow (FCF) for Insulet Corp. (PODD)?
- The 5Y average free cash flow (FCF) for PODD stock is $85.08M.
- What is the 10Y average free cash flow (FCF) for Insulet Corp. (PODD)?
- The 10Y average free cash flow (FCF) for PODD stock is $-63.65M.
- What is the 15Y average free cash flow (FCF) for Insulet Corp. (PODD)?
- The 15Y average free cash flow (FCF) for PODD stock is $-38.74M.
- What is the 20Y average free cash flow (FCF) for Insulet Corp. (PODD)?
- The 20Y average free cash flow (FCF) for PODD stock is $-47.51M.
PODD Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2026-03-31 | $412.20M |
| 2025-09-30 | $421.20M |
| 2025-03-31 | $279.30M |
| 2024-09-30 | $246.90M |
| 2024-03-31 | $170.30M |
| 2023-09-30 | $-14.80M |
| 2023-03-31 | $-45.30M |
| 2022-09-30 | $-63.00M |
| 2022-03-31 | $-151.90M |
| 2021-09-30 | $-199.10M |
| 2021-03-31 | $-119.90M |
| 2020-09-30 | $-14.69M |
| 2020-03-31 | $-63.34M |
| 2019-09-30 | $-72.59M |
| 2019-03-31 | $-125.70M |
| 2018-09-30 | $-129.71M |
| 2018-03-31 | $-28.14M |
| 2017-09-30 | $-11.25M |
| 2017-03-31 | $-40.04M |
| 2016-09-30 | $-45.44M |
| 2016-03-31 | $-29.00M |
| 2015-09-30 | $891000.00 |
| 2015-03-31 | $-7.23M |
| 2014-09-30 | $-10.85M |
| 2014-03-31 | $-4.86M |
| 2013-09-30 | $-5.30M |
| 2013-03-31 | $-31.72M |
| 2012-09-30 | $-42.35M |
| 2012-03-31 | $-36.41M |
| 2011-09-30 | $-37.24M |
| 2011-03-31 | $-42.67M |
| 2010-09-30 | $-42.58M |
| 2010-03-31 | $-49.59M |
| 2009-09-30 | $-59.02M |
| 2009-03-31 | $-86.40M |
| 2008-09-30 | $-93.03M |
| 2008-03-31 | $-65.66M |
| 2007-09-30 | $-55.87M |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy